双特异单链抗体靶向治疗急性白血病  

Targeted therapy with bispecific single chain antibodies for acute leukemia

作　　者：崔鹤[1] 张王刚[2] 

机构地区：[1]内蒙古医科大学附属医院血液内科,内蒙古呼和浩特010050 [2]西安交通大学第二附属医院血液内科,陕西西安710004

出　　处：《现代肿瘤医学》2015年第9期1283-1287,共5页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:0817 18110232)

摘　　要：目前除急性早幼粒细胞白血病(acute promyelocytic leukemia,APL)以外的急性白血病(acute leukemia,AL)疗效堪忧,急需研发新的治疗药物。采用基因工程抗体技术制备的双特异性单链抗体能同时结合两个特异性抗原,与其他抗体药物相比有明显的优越性,是一种有很好临床应用前景的免疫治疗药物,本文对双特异性单链抗体靶向治疗急性白血病的最新进展做一综述。At present,there is a urgent need to develop new drugs for acute leukemia patients because of their poor effect except for acute promyelocytic leukemia. The bispecific single chain antibodies can combine with two specific antigens using gene engineering antibody technology,show more obvious advantage than other antibody drugs,and po-tential prospect in clinical application. We described the current new targeted therapy with bispecific single chain anti-bodies for acute leukemia in this article.

关 键 词：双特异性单链抗体 靶向治疗 急性白血病 

分 类 号：R730.51[医药卫生—肿瘤] R733.71[医药卫生—临床医学]